<DOC>
	<DOCNO>NCT00004816</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate safety immunogenicity single multiple dos M-T412 , chimeric murine-human anti-CD4 monoclonal antibody , patient multiple sclerosis . II . Evaluate pharmacokinetics M-T412 . III . Obtain preliminary data clinical response M-T412 .</brief_summary>
	<brief_title>A Maintenance Extension Phase I Pilot Study Chimeric Anti-CD4 Antibody M-T412 Patients With Multiple Sclerosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This open label , dose escalate study . Escalating dose M-T412 administer cohort 5 patient receive single dose intravenously 2 hour . Patients complete single dose assessment M-T412 may receive 3 additional single dose M-T412 IV 2 hour , repeat dose give least 1 month apart . Then , patient receive one dose level M-T412 IV 2 hour 3 month interval period 12 month total 5 dos . Once recovery CD4 cell obtain , next schedule infusion M-T412 begin . Patients omit study CD4 cell remain attenuated follow 2 scheduled infusion session . Patients follow 3 , 6 , 12 , 24 month first infusion .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis chronic , advance , progressive multiple sclerosis ( MS ) Prior/Concurrent Therapy Biologic therapy : No sensitivity murine proteins No prior treatment time antiCD4 antibody , murine antibody , antiT cell antibody ( e.g. , xenologous human ) At least 4 week since use biological agent Chemotherapy : No concomitant chemotherapy At least 3 month since prior chemotherapy Endocrine therapy : No concomitant steroidal therapy At least 3 month since prior steroidal therapy Radiotherapy : No total lymphoid irradiation prior study No concomitant radiotherapy At least 3 month since prior radiotherapy Other : No use investigational drug within 30 day prior study Patient Characteristics Age : 21 75 Hematopoietic : Hemoglobin least 10 g/dL WBC least 4000/mm3 Granulocyte count least 1500/mm3 Platelet count least 100,000/mm3 CD4+ lymphocyte count least 300 cells/mm3 Other : Not pregnant lactate Effective contraception require fertile patient 3 month prior study No substance abuse ( e.g. , drug alcohol ) Not HIV positive No AIDSRelated Complex ( ARC ) No serum antibody HIV Negative serum antibody test HIV within 1 month prior study No underlie medical psychiatric condition</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>neurologic psychiatric disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>